Illuminating the mechanism of IL-6-mediated immunotherapy resistance.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 36652910.
- Also identified by DOI 10.1016/j.xcrm.2022.100901 and PMC identifier 9873941.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Huseni et al. report that IL-6-STAT3 signaling negatively impacts the anti-tumor function of cytotoxic T cells. Targeting IL-6 signaling may enhance tumor responses to immune checkpoint blockade therapy.
Medical subject headings
- Interleukin-6
- Neoplasms